PMID- 2931452
OWN - NLM
STAT- MEDLINE
DCOM- 19851104
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 76
IP  - 3
DP  - 1985 Sep
TI  - Identification of malignant plasma cell precursors in the bone marrow of multiple 
      myeloma.
PG  - 1243-51
AB  - Precursors of plasma cells were studied in the bone marrow of 28 patients with 
      multiple myeloma, plasma cell leukemia, and benign monoclonal gammopathy. Pre-B 
      and B cell populations were analyzed with anti-B monoclonal antibodies 
      corresponding to the clusters standardized at the Leucocyte Typing Workshops in 
      Paris and Boston (CD9, CD10, CD19-22, CD24). In advanced forms of plasma cell 
      malignancies, such as cases of multiple myeloma in stages II and III and of 
      plasma cell leukemia, some cells of lymphoid morphology expressed common acute 
      lymphoblastic leukemia antigen (CALLA, CD10) and HLA-DR, but contained no 
      detectable terminal deoxynucleotidyl transferase enzyme. These CALLA+ cells were 
      absent in benign monoclonal gammopathies. In multiple myeloma, the CALLA+ cells 
      were negative for surface and cytoplasmic immunoglobulins (Ig), and, unlike 
      CALLA+, terminal deoxynucleotidyl transferase (TdT+) pre-B cells in the normal 
      bone marrow also failed to react with antibodies to B cell-associated antigens 
      such as CD9, CD19, CD22, and CD24. The CALLA+, Ig- cells could be regarded as 
      preplasmacytic since, after having been separated and stimulated with the phorbol 
      ester 12-0-tetradecanoyl-phorbol-13 acetate in vitro, they transformed into 
      plasma cells and synthesized the same heavy and light chains as myeloma cells.
FAU - Caligaris-Cappio, F
AU  - Caligaris-Cappio F
FAU - Bergui, L
AU  - Bergui L
FAU - Tesio, L
AU  - Tesio L
FAU - Pizzolo, G
AU  - Pizzolo G
FAU - Malavasi, F
AU  - Malavasi F
FAU - Chilosi, M
AU  - Chilosi M
FAU - Campana, D
AU  - Campana D
FAU - van Camp, B
AU  - van Camp B
FAU - Janossy, G
AU  - Janossy G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Antigens, Differentiation, B-Lymphocyte)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antigens, Surface)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, Differentiation, B-Lymphocyte
MH  - Antigens, Neoplasm/analysis
MH  - Antigens, Surface/analysis
MH  - Bone Marrow/*pathology
MH  - Cell Differentiation/drug effects
MH  - Cells, Cultured
MH  - Female
MH  - Hematopoietic Stem Cells/*classification/immunology/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/blood/*pathology
MH  - Neprilysin
MH  - Phenotype
MH  - Plasma Cells/*classification/immunology/pathology
MH  - Tetradecanoylphorbol Acetate/pharmacology
PMC - PMC424031
EDAT- 1985/09/01 00:00
MHDA- 1985/09/01 00:01
PMCR- 1985/09/01
CRDT- 1985/09/01 00:00
PHST- 1985/09/01 00:00 [pubmed]
PHST- 1985/09/01 00:01 [medline]
PHST- 1985/09/01 00:00 [entrez]
PHST- 1985/09/01 00:00 [pmc-release]
AID - 10.1172/JCI112080 [doi]
PST - ppublish
SO  - J Clin Invest. 1985 Sep;76(3):1243-51. doi: 10.1172/JCI112080.